BFBIO Pharmaceuticals: Major
Health Technology
Mkt Cap
12.2B
P/E (TTM)
20.68
EPS
5.52
ROE
12.25%
Div Yield
—
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 5.84B | 3.66B | 1.81B | 1.52B | 1.75B | |
| Cost of Goods Sold | -3.60B | -2.16B | -1.37B | -1.08B | -993.99M | |
| Gross Profit | 2.24B | 1.50B | 434.55M | 437.22M | 760.81M | |
| SG&A Expenses | -1.49B | -773.14M | -161.13M | -193.99M | -157.65M | |
| Research & Development | -7.85M | -6.31M | -2.20M | -3.71M | -6.88M | |
| Depreciation | -191.92M | -35.57M | -33.78M | -28.33M | -23.43M | |
| Other Operating Expense | -17.15M | -17.63M | -22.78M | 4.11M | 7.25M | |
| Total Operating Expense | -5.10B | -2.95B | -1.56B | -1.27B | -1.14B | |
| Operating Income (EBIT) | 732.69M | 705.40M | 250.65M | 247.33M | 610.41M | |
| Interest Income | 20.21M | 6.48M | 750.1K | 8.33M | 2.56M | |
| Interest Expense | -123.98M | -149.85M | -152.13M | -64.40M | -25.27M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | 89.32M | 13.68M | 82.26M | 155.65M | 57.52M | |
| Total Non-Operating Income | -12.15M | -129.80M | -68.14M | 101.43M | 35.19M | |
| Pre-Tax Income | 720.54M | 575.61M | 182.51M | 348.76M | 645.61M | |
| Income Tax | -273.39M | -190.19M | -33.46M | -41.78M | -37.62M | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |
| Net Income | 447.15M | 385.41M | 149.05M | 306.98M | 607.99M | |
| EBITDA | 926.30M | 741.52M | 284.98M | 275.66M | 633.85M | |
| EPS (Basic) | 5.52 | 6.09 | 2.35 | 16.16 | 32.00 | |
| EPS (Diluted) | 5.52 | 6.09 | 2.35 | 16.16 | 32.00 | |
| Gross Margin | 38.30% | 40.89% | 24.01% | 28.75% | 43.36% | |
| Operating Margin | 12.55% | 19.28% | 13.85% | 16.26% | 34.79% | |
| EBITDA Margin | 15.87% | 20.27% | 15.75% | 18.13% | 36.12% | |
| Pre-Tax Margin | 12.34% | 15.73% | 10.09% | 22.93% | 36.79% | |
| Net Margin | 7.66% | 10.53% | 8.24% | 20.19% | 34.65% |